1 in 2 girls are quitting sport due to periods, according to new global report by PUMA and Modibodi®
2.5.2022 15:00:00 EEST | Business Wire | Press release
As part of the launch of their new leak-proof underwear collection, global sports company PUMA and leak-proof apparel company Modibodi® have commissioned a global survey that investigated the reason girls are leaving sport; shining a light on the numbers that really matter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005440/en/
Global sports company PUMA and leak-proof apparel company Modibodi® have commissioned a global survey that investigated the reason girls are leaving sport. The statistics unearthed were shocking, with 1 in 2 teens skipping sport because of their period. (Photo: Business Wire)
Sport is all about numbers. And when it comes to the celebration of sport, the goals kicked, and games won are the numbers that take centre stage. But there’s series of numbers that are less well-known: the number of girls leaving sport daily, due to shame and fear of leaks.
The statistics unearthed were shocking, with 1 in 2 teens skipping sport because of their period. The PUMA and Modibodi® global survey discovered that for many girls, sport stops because of embarrassment, pain or fear of leaks during their period. The survey insights show how the culture and lack of innovation around periods is holding girls back from participating in sport. The discomfort of disposable products coupled, from a coaching perspective, with a lack of education and training, has meant that the result is female players finding the fear of leaking psychologically impacting their sporting performance.
With the subject of periods going undiscussed in the sports world, Australian PUMA athlete and AFL Collingwood star, Sabrina Frederick, is keen to break the stigma: “I was one of the ones who stayed in sport. But for many girls, that’s not a reality. Periods shouldn’t stop young girls from participating in sport. These are numbers we need to address, to keep girls in sport longer.”
Ali Riley, New Zealand PUMA athlete and captain of the Football Ferns, says “It's time to break the silence and help women and girls stay comfortable and active during their period. What’s fantastic about the PUMA x Modibodi active underwear collection is that it has been designed specifically to help making playing sport on your period more possible than ever before.”
The PUMA x Modibodi collection replaces the need for disposable pads, liners and tampons as you play. Modibodi’s proprietary Modifier Technology™ wicks moisture and sweat, locks away fluid and odour and keeps you feeling fresh and dry, without the discomfort of disposables.
“3 in 5 teens skip sport due to fear of leaking or revealing their period which is why we are thrilled to launch this collection with PUMA and together normalize menstruation and tackle the stigma that women can't be active on their periods or when experiencing any of life’s leaks.” said Kristy Chong, CEO and Founder, Modibodi
“Our data also shows that 1 in 2 experience discomfort from disposable menstrual products like pads and tampons when participating in sport or physical exercise- so by releasing this range of leak-proof underwear we are hoping to make playing sport on your period more comfortable, more protected, and more possible than ever. Changing the world should be as easy as changing your underwear. Waste-free, leak-free, worry-free protection.”
Under the “She Moves Us” platform, PUMA together with Modibodi believe that everybody who wants to participate in exercise or sport should be given the opportunity to stay active and play.
“3 in 4 women believe periods need to be more openly discussed in the sports world and it’s why we are proud to partner with Modibodi to shine a light on these numbers that really matter in sports.” said Erin Longin, Global Director Running and Training business unit at PUMA. “As a global brand, we felt it important to do our part to address this issue.”
As part of the launch, PUMA and Modibodi will work with PUMA’s She Moves Us charity partner, Women Win, to donate bundle packs to 500 girls and women in need. “Period poverty is a huge issue globally but one that isn’t nearly spoken about enough. Making sustainable menstrual products widely available is something that needs to be addressed urgently and that is why I am so proud to be a part of the PUMA x Modibodi collaboration”, says Jodie Williams, British sprinter and PUMA athlete.
The PUMA x Modibodi collection consists of 3 styles of active underwear: thong, brief and boyshort, designed to suit every body. Each style is available in two colour ways: dark slate and grape wine and to maximise comfort whilst playing sports, includes a unique, 3mm thin gusset with Modibodi’s scientifically proven absorbent Modifier Technology ™.
With a wider waist band to ensure security whilst playing and aerated side panels designed for comfort and to maximise airflow, the PUMA x Modibodi active underwear range offers women and girls the ability to stay active without having to worry about leaks, while reducing their monthly waste from period products.
The PUMA x Modibodi active underwear collection is available in selected stores and online at modibodi.com and puma.com
|
PUMA |
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 70 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 14,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
|
MODIBODI |
Founded in 2013, Modibodi® is Australia’s original leak-proof apparel brand, designing underwear, swimwear, active wear, maternity wear and reusable nappies to replace disposable hygiene products and offer a sustainable solution to manage periods, incontinence, discharge, breast milk leaks, sweat and more. Modibodi is warm, authentic and human. We help people with all kinds of leaky bodies get on with their lives. We’re plain speaking and taboo breaking. We’re comfortable in our own skin and not embarrassed to talk about leaky bodies – because they’re part of life. We offer a range of products and sizes across our three brands: Modibodi®, Modibodi RED for tweens and teens, and Modibodi Men to manage incontinence, sweat and chafing. Our Modibodi leak-proof products have been scientifically tested and proven to absorb fluid, resist odour, and keep you dry, thanks to the brand’s patented technology which keeps you feeling comfortable and confident and reduces the impact on the environment. Modibodi is committed to sustainability and social impact, helping end period poverty and normalising conversations about periods and leaks through education and supporting people in need globally. To date, Modibodi has sold millions of garments worldwide, saving billions of single-use disposable hygiene products such as pads, liners and tampons from ending up in landfill.
Changing the world should be as easy as changing your underwear. Waste-free, leak-free, worry- free protection.
Source: PUMA and Modibodi® Global Survey into Girls Leaving Sport
Survey of 1000 girls and women globally, focusing the impact periods have on their relationship to sport, it psychologically impacts on performance as well as the degrees of support received from coaches, schools' education and physical product technology.
Countries: Australia, New Zealand, USA, UK, Europe
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005440/en/
Contact information
Media Contact:
PUMA
Gudrun Cäemmerer
Teamhead Global PR
gudrun.caemmerer@puma.com
Phone +49 173 2199376
Modibodi
Lucy Lamming
PR & Partnerships Lead
lucylamming@modibodi.com
Phone +61 403 562 993
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
